Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Neuropharmacology. 2020 Sep 17;180:108296. doi: 10.1016/j.neuropharm.2020.108296

Figure 3. The CRF1 antagonist R121919 alters basal but not CRF-stimulated inhibitory control of male and female CRF1+ CeA neurons.

Figure 3.

(A) Representative voltage-clamp recordings from male (top) and female (bottom) CRF1+ CeA neurons during focal application of aCSF (upper) or R121919 (1μM; lower). (B) Quantification of sIPSC frequency in male and female CRF1+ CeA neurons following aCSF or R121919 (1μM) focal application expressed in Hz (upper left) and percent of control (upper right). Quantification of sIPSC amplitude in male and female CRF1+ CeA neurons following aCSF or R121919 (1μM) focal application expressed in picoamps (lower left) and percent of control (lower right). (C) Representative voltage-clamp recordings from male (top) and female (bottom) CRF1+ CeA neurons during focal application of R121919 (1μM; upper) or R121919 (1μM) plus CRF (200nM) co-application (lower). (D) Quantification of sIPSC frequency in male and female CRF1+ CeA neurons following focal application of R121919 (1μM) and R121919 (1μM) plus CRF (200nM) co-application expressed in Hz (upper left) and percent of control (upper right). Quantification of sIPSC amplitude in male and female CRF1+ CeA neurons following focal application of R121919 (1μM) and R121919 (1μM) plus CRF (200nM) co-application expressed in picoamps (lower left) and percent of control (lower right). * = p < 0.05 by two-way RM ANOVA , *** = p < 0.001 by two-way RM ANOVA, # = p < 0.05 by one-sample t-test.